Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn [13]

New England Journal of Medicine

Volumn 354, Issue 20, 2006, Pages 2189-

  Hallberg, Pär ^a   Odlind, Viveca ^a   Sjöblom, Viktoria ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

CONGENITAL DISORDER; CONGENITAL HEART MALFORMATION; DISEASE SEVERITY; HUMAN; LETTER; MENTAL DISEASE; MOTHER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; THIRD TRIMESTER PREGNANCY;

EID: 33646689330     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. FDA public health advisory: paroxetine. Washington, D.C.: Center for Drug Evaluation and Research, Food and Drug Administration, December 2005. (Accessed May 1, 2006, at http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm.)